Castration-Resistant Prostate Carcinoma

Castration-Resistant Prostate Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 222
Recruiting: 123
Ph III recruiting: 12
Growth YoY: +25%
Industry share: 45%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (94)

clinicaltrialsPublishedShowing 51–80 of 80 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05457257	Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations	active not recruiting	Phase 4	43	AstraZenecaINDUSTRY	1	Apr 21, 2026	clinicaltrials
NCT05960578	Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study	active not recruiting	Phase 2	8	University of WashingtonOTHER	1	Apr 14, 2026